STAAR Surgical Taps Former CEO David Bailey as Chief Commercial…

Event summary

STAAR Surgical appoints David Bailey, former CEO (2001–2008), as Chief Commercial Officer, reporting to CEO Warren Foust.
Bailey previously led STAAR's commercial pivot toward phakic IOL-based refractive surgery and secured FDA approval for ICL in 2005.
ICL revenues have grown over tenfold since Bailey's tenure, reaching approximately $320 million today.
Bailey brings 30+ years of executive experience in ophthalmology and medical technology across the U.S., Europe, and Asia.

The big picture

STAAR Surgical's appointment of David Bailey as Chief Commercial Officer underscores its focus on accelerating revenue growth and expanding the commercial potential of its EVO ICL product line. Bailey's return brings deep industry experience and a track record of successfully pivoting STAAR's commercial strategy toward phakic IOL-based refractive surgery. The move comes as laser refractive volumes decline globally, positioning STAAR to capture market share with its proprietary Collamer technology and EVO ICL offerings.

What we're watching

Execution Risk: Whether Bailey can replicate past success in driving revenue growth and expanding market share for EVO ICL.
Market Dynamics: The pace at which lens-based surgery gains ground over declining laser refractive volumes globally.
Innovation Roadmap: How STAAR's innovation roadmap will further widen its advantages over laser-based alternatives and open new markets.